Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.